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Abstract Thyroid hormone stimulates myoblast differentiation,
through an inhibition of AP-1 activity occurring at the onset of
differentiation. In this study we found that the T3 nuclear
receptor c-ErbAK1 (T3RK1) is involved in a mechanism
preserving the duration of myoblast proliferation. Independently
of the hormone presence, T3RK1 represses avian MyoD
transcriptional activity. Using several mutants of T3RK1, we
found that the hinge region plays a crucial role in the inhibition of
MyoD activity. In particular, mutations of two small basic
sequences included in K helices abrogate the T3RK1/MyoD
functional interaction. Similarly, the T3 receptor also represses
myogenin transcriptional activity. Therefore, despite stimulating
avian myoblast differentiation by a T3-dependent pathway not
involving myogenic factors, T3RK1 contributes to maintain an
optimal myoblast proliferation period by inhibiting MyoD and
myogenin activity. ß 2001 Federation of European Biochemi-
cal Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Thyroid hormone is a major regulator of muscle develop-
ment. In vivo, this hormone not only increases the number [1]
and the diameter of myo¢bers [2], but also in£uences their
metabolic and contractile features [3,4]. In addition, triiodo-
thyronine (T3) promotes fetal to neonatal myosin isoform
transition [5]. In vitro studies of our team have provided ¢rst
evidence that the T3 myogenic in£uence includes an increased
myoblast withdrawal rate from the cell cycle leading to a
stimulation of terminal di¡erentiation [6,7]. Moreover, over-
expression experiments established that the T3 nuclear recep-
tor c-ErbAK1 (T3RK1) is involved in the myogenic activity of
the hormone [8]. However, these data raised a contradiction
between in vivo and in vitro experiments, by the observation
that T3 stimulates muscle development despite it reduces the
duration of myoblast proliferation.
To conciliate these data, we searched for other mechanisms
leading to a preservation of the proliferation period. Interest-
ingly, a crucial mechanism involved in the T3 myogenic in£u-
ence, repression of AP-1 activity (Jun/Fos transcriptional ac-
tivity) by liganded T3RK1, is only functional at a particular
stage of myoblast progression in the myogenic program char-
acterized by RXR expression [9,10]. In the same line, as
MyoD is involved in the induction of myoblast withdrawal
from the cell cycle [11,12], we have studied the possibility that
a T3RK1-dependent mechanism could in£uence the activity of
this myogenic factor. In the present work, we bring evidence
that independently of the T3 presence, T3RK1 inhibits CMD1
(avian MyoD) transcriptional activity, through a functional
interaction involving the hinge domain of the receptor.
2. Materials and methods
2.1. Cell cultures
Quail myoblasts of the QM7 cell line [13] were seeded at a plating
density of 7000 cells/cm2. They were grown in Earle 199 medium
supplemented with tryptose phosphate broth (0.2%), L-glutamine
(2 mM), gentamicin (50 Wg/ml), and fetal calf serum (10%). Serum
was T3 depleted according to [14]. After hormonal depletion, T3 and
T4 levels measured by radioimmunoassay were always lower than the
detection limit of the assay.
2.2. Plasmids and reporter genes
The myogenin-CAT reporter plasmid contains the 3131/+40 frag-
ment of the chicken myogenin promoter upstream the chlorampheni-
col acetyltransferase (CAT) coding sequence [15]. The expression vec-
tors for chicken c-ErbAK1, c-ErbAK1 v1^36 and MyoD (pRSV
c-erbAK1, pSG5-v1 and pRSV CMD1) have previously been described
[16^18]. The expression vector encoding murine c-ErbAK1 (pSG5
c-erbAK1) was constructed by insertion of a 1.2 kb fragment encoding
murine c-ErbAK1, cloned by PCR, in pSG5 vector. The expression
vector encoding murine c-ErbAK1 v1^256 (pSG5 K1t) has been de-
scribed elsewhere [19]. The expression vector for rat Gal4/c-ErbAK1
(pSVGal4K1) has been provided by Dr F. Flamant (ENS Lyon,
France). The expression vectors for rat c-ErbAK1-D, c-ErbAK1-1,
c-ErbAK1-2, and c-ErbAK1-3 mutants (pMT2 c-ErbAK1-D, pMT2
c-ErbAK1-1, pMT2 c-ErbAK1-2, and pMT2 c-ErbAK1-3) have been
constructed by Lee and Mahdavi [20]. Mutant and wild-type c-Er-
bAK1 proteins used in this study are presented in Fig. 1. The expres-
sion vector encoding N-CoR (pCEP4 N-CoR) has previously been
described [21].
2.3. Transient transfections and CAT assays
Transient transfections were performed using the calcium phos-
phate co-precipitation procedure [9]. 1 Wg of pCMV L-galactosidase
expression vector was cotransfected to provide an internal control of
transfection e⁄ciency. After cell exposure to precipitates for 24 h, the
DNA-containing medium was replaced with fresh medium containing
T3 (1038 M) when indicated, and the cells were grown for a further 24
h. L-Galactosidase activity was measured as previously described [22].
CAT enzymatic activity was measured by following the kinetics of
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chloramphenicol acetylation [9]. Results are expressed as percentage
of control values after L-galactosidase normalization.
In parallel experiments, c-ErbAK wild-type and mutant expression,
as well as localization of the proteins, was assessed in cytoimmuno-
£uorescence experiments using RHTII antibody raised against the
COOH-terminus of the protein [23], according to the procedure de-
scribed by Wrutniak et al. [23].
2.4. Statistical analysis
Statistical analyses were performed using the paired t-test [24].
3. Results
3.1. c-ErbAK1 expression inhibits CMD1 transcriptional
activity in myoblasts
The in£uence of avian c-ErbAK1 expression on CMD1
transcriptional activity was studied in transient transfection
experiments using the QM7 avian myoblast line, with a re-
porter gene driven by a minimal myogenin promoter respond-
ing to CMD1 [15]. Whereas CMD1 induced an 11-fold stim-
ulation of myogenin promoter basal activity (P6 0.001), this
in£uence was fully abrogated by coexpression of avian c-Er-
bAK1 (11-fold inhibition relative to CMD1 alone; P6 0.001,
Fig. 2A). Moreover, addition of 1038 M T3 in the culture
medium did not signi¢cantly in£uence CMD1 transcriptional
activity, and did not a¡ect the inhibitory activity of T3RK1.
Similar data were obtained using another promoter regulated
by MyoD (L-tropomyosin promoter, data not shown).
3.2. The hinge domain of c-ErbAK1 is involved in the inhibition
of CMD1 transcriptional activity
To identify the T3RK1 functional domains involved in the
inhibition of CMD1 transcriptional activity, we assessed the
activity of a truncated form of the receptor [25] harboring a
deletion of the NH2-terminus, c-ErbAK1 v1^36. This T3RK1
mutant displayed a signi¢cant inhibitory in£uence on CMD1
transcriptional activity (2-fold inhibition of CAT activity rel-
atively to CMD1 alone, P6 0.025, Fig. 2B). When corrected
for the frequency of cells displaying a c-ErbA staining in the
nucleus assessed in cytoimmuno£uorescence experiments, the
recorded inhibition was of the same magnitude than observed
for the integral receptor (Table 1). These data suggest that the
amino-terminal part of c-ErbAK1 including amino acids 1^36
is not essential for the functional interaction with CMD1.
In additional experiments, we used several mutants of mur-
ine or rat c-ErbAK1. This approach was justi¢ed by the very
high conservation degree of the amino acid sequence of the T3
Fig. 1. Wild-type and mutants of the c-ErbAK1 receptor used in
this study. Schematic representation of c-ErbAK1, c-ErbAK1 v1^36,
c-ErbAK1 v1^256, Gal4/c-ErbAK1, c-ErbAK1-D, c-ErbAK1-1, c-Er-
bAK1-2 and c-ErbAK1-3 proteins. A/B: T3-independent transactiva-
tion domain. C: DNA binding domain. D: Hinge domain. E: Hor-
mone binding domain.
Fig. 2. c-ErbAK1 inhibits CMD1 transcriptional activity. Cells were transfected with 1 Wg/dish of the myogenin-CAT reporter gene and, when
indicated, 2 Wg of CMD1, avian c-ErbAK1 (A), c-ErbAK1 v1^36 (B), murine c-ErbAK1 (C) and Gal4/c-ErbAK1 (D) expression vectors. Results
are expressed as percentages of CAT activity in control cells, after L-galactosidase normalization. Data are presented as the means þ S.E.M. of
¢ve (A), four (B) or three (C and D) separate transfection experiments.
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receptor among species [26]. As expected, like its avian ortho-
logue, murine T3RK1 displayed also a repressive in£uence on
CMD1 transcriptional activity, by inducing a 2.1-fold inhibi-
tion (P6 0.025, Fig. 2C). A same in£uence was recorded us-
ing murine MyoD (data not shown). Moreover, a rat c-Er-
bAK1 mutant, Gal4/c-ErbAK1, in which the NH2-terminal
domain including the ¢rst 120 amino acids have been replaced
by the DNA binding domain of the yeast Gal4 transcription
factor, also inhibited CMD1 transcriptional activity (4.6-fold
inhibition relative to CMD1 alone; P6 0.001, Fig. 2D).
Therefore, despite minor changes in their amino acid se-
quence, all T3RK1 tested shared the ability to repress
CMD1 transcriptional activity. After correction for transfec-
tion e⁄ciency, it also appeared that their inhibitory potential
was quite similar (Table 1). Therefore, these data brought
con¢rmation that the NH2-terminus sequence of the receptor
is not involved in this functional interaction.
Interestingly, deletion of amino acids 1^256 (amino-termi-
nal sequence, hinge region and a small part of the ligand
binding domain) abolished the ability of T3RK1 to inhibit
CMD1 activity, thus ruling out the hypothesis that the car-
boxy-terminal domain of the receptor plays a signi¢cant role
in T3RK1/CMD1 functional interactions (Fig. 3A).
This set of data suggested that the region including amino
acids 120^256, corresponding to the hinge domain and the
beginning of the ligand binding domain of T3RK1, is involved
Table 1
Comparison of the inhibition of CMD1 transcriptional activity by
c-ErbA wild-type and mutants corrected for transfection e⁄ciency
3T3 +T3
Avian c-ErbAK1 13.9 13.1
c-ErbAK1 v1^36 16.8 14.9
Murine c-ErbAK1 17.0 16.2
Gal4/c-ErbAK1 17.6 13.3





The inhibition corrected for transfection e⁄ciency (CI) has been cal-
culated according to the following equation: CI = % inhibition/FOC
where % inhibition = 1003[(CAT activity CMD1+c-ErbA)U100/
(CAT activity CMD1)], FOC (frequency of overexpressing cells) = %
of cells with overexpressed c-ErbA located in the nucleus. This fre-
quency has been established by counting the number of nuclei
stained with an antibody raised against c-ErbA (cytoimmuno£uores-
cence experiments) in three independent transfection experiments.
Fig. 3. Mutation in the hinge domain abrogates the repression of CMD1 transcriptional activity by c-ErbAK1. Cells were transfected with
1 Wg/dish of the myogenin-CAT reporter gene and, when indicated, 2 Wg of CMD1, c-ErbAK1 v1^256 (A), c-ErbAK1-D (B), c-ErbAK1-1 (C),
c-ErbAK1-2 (D) and c-ErbAK1-3 (E) expression vectors. F: In£uence of N-CoR on the inhibition of CMD1 transcriptional activity by
c-ErbAK1. Cells were transfected with 1 Wg/dish of the myogenin-CAT reporter gene, and when indicated 2 Wg of CMD1, 2 Wg of avian
c-ErbAK1 and 4 Wg of N-CoR expression vectors. Results are expressed as percentages of CAT activity in control cells, after L-galactosidase
normalization. Data are presented as the means þ S.E.M. of three (B, C, D, E) or four (A, F) separate transfection experiments.
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in the inhibition of CMD1 transcriptional activity. To de¢ne
more accurately the sequence involved in the T3RK1/CMD1
functional interaction, we studied the in£uence of a speci¢c
deletion of the hinge domain, by coexpressing c-ErbAK1-D
and CMD1. In agreement with our previous data, this
T3RK1 mutant did not inhibit CMD1 transcriptional activity
(Fig. 3B). In additional experiments, we overexpressed a T3
receptor mutant (c-ErbAK1-3) in which the basic K134RK and
R188RK sequences were substituted by the neutral residues
TIT [20]. These mutations fully abrogated the ability of the
receptor to inhibit CMD1 transcriptional activity (Fig. 3C). In
addition, T3RK1 mutants bearing a similar mutation in only
one of the K134RK and R188RK sequences, also failed to
inhibit CMD1 transcriptional activity (Fig. 3D and E). These
results demonstrated that these two sequences are greatly in-
volved in the T3RK1/CMD1 functional interaction.
The hinge region of T3RK1 includes nuclear co-repressor
interaction domains close to the R188RK basic sequence. We
observed that overexpression of the nuclear hormone co-re-
pressor, N-CoR [21], signi¢cantly decreased CMD1 transcrip-
tional activity (P6 0.01), as already demonstrated by Bailey et
al. [27]. However, it did not in£uence the repression induced
by T3RK1 (Fig. 3F). These data clearly suggest that the func-
tional interaction between the T3 receptor and the myogenic
factor did not involve competition for the recruitment of this
co-repressor.
3.3. Myogenin transcriptional activity is also inhibited by
c-ErbAK1
In order to extend our study to another myogenic factor,
we studied the in£uence of T3RK1 on the transcriptional ac-
tivity of myogenin, which is essentially involved in the induc-
tion of myoblast terminal di¡erentiation. Whereas myogenin
expression induced a 10-fold stimulation of the reporter basal
activity, this in£uence was fully abrogated by coexpression of
avian c-ErbAK1 (13-fold inhibition relatively to myogenin
alone, P6 0.001; Fig. 4). These data indicate that T3RK1
functional interaction with myogenic factors is not restricted
to CMD1, and that, independently of the hormone, the T3
receptor could be also involved in mechanisms leading to a
negative control of myoblast di¡erentiation.
4. Discussion
In the present study, we brought evidence that c-ErbAK1
represses CMD1 transcriptional activity by a T3-independent
mechanism. As hormone binding induces conformational
changes in the COOH-terminus of the receptor leading to
crucial modi¢cations in its functionality, this result is consis-
tent with the observation that this part of the receptor does
not play any signi¢cant role in this unexpected activity. In
agreement with these data, the product of the v-ErbA onco-
gene, lacking the AF2 sequence located in the ligand binding
domain of the receptor, also inhibits CMD1 transcriptional
activity (data not shown). Also interesting is the observation
that this activity of the T3 receptor is not restricted to the
avian protein and appears to be extended to mammalian re-
ceptors: mouse and rat T3RK1 repress avian and mammalian
MyoD activity (data not shown).
In search for the functional domains of the receptor in-
volved in this functional interaction by using several T3RK1
mutants, we concluded that the NH2-terminal sequence (A/B
domains) and the DNA binding domain (C domain) are not
needed to promote the inhibition of CMD1 activity. However,
deletion of almost all the A/B domain (c-ErbAK1 v1^36) sig-
ni¢cantly reduced this in£uence, in agreement with previous
data indicating that in transient transfection experiments, this
protein displays a dual cytoplasmic and nuclear localization
[28], thus altering the e⁄ciency of this protein at the nuclear
level. This possibility is well supported by the observation that
after correction for the frequency of nuclear localization of
this mutant, its inhibitory activity is not di¡erent of that re-
corded for the integral receptor (Table 1).
This set of data underlines the importance of the T3RK1
hinge region (D domain). As expected from these results, all
mutants deleted from this functional domain are unable to
inhibit CMD1 transcriptional activity (c-ErbAK1 v1^256,
c-ErbAK1-D). Interestingly, the D domain harbors several short
basic sequences highly conserved in all species [26], suggesting
a particular importance for the receptor function. In addition,
similar highly conserved sequences have been described in the
basic DNA binding domain of myogenic factors [29]. More-
over, several reports have established that such domains are
involved in protein^protein interactions with various tran-
scription factors, including HLH and zinc ¢nger-containing
proteins [30^32]. In particular, the MyoD basic domain has
been shown to physically interact with the basic domain of
Twist [33]. Therefore, this negative functional interaction be-
tween CMD1 and c-ErbAK1 could involve the basic helices of
the two proteins. In agreement with this possibility, we found
that mutations of one or two of these short basic sequences in
T3RK1 (K134RK in the A helix at the beginning of the
D domain and R188RK at the end of an K helix of the
D domain terminus [34,35]), fully abrogated the ability of
the T3 receptor to inhibit CMD1 transcriptional activity.
Several data argue in favor of a direct T3RK1/CMD1 func-
tional interaction. First, overexpression of N-CoR, a co-re-
pressor interacting with nuclear receptors and MyoD [21,27]
is without in£uence on the inhibition of CMD1 activity by the
T3 receptor. Second, in addition to co-repressors, as this in-
£uence occurs independently of the T3 presence, the ligand-
dependent binding of co-activators to c-ErbA is clearly not
involved in the T3RK1/CMD1 functional interaction. These
observations rule out the possibility that competition between
the receptor and the myogenic factor for the recruitment of a
common co-regulator could be involved in the regulation de-
scribed in this study. Moreover, a direct interaction is also
Fig. 4. c-ErbAK1 inhibits myogenin transcriptional activity. Cells
were transfected with 1 Wg/dish of the myogenin-CAT reporter gene,
2 Wg of myogenin and/or c-ErbAK1 expression vectors. Results are
expressed as percentages of CAT activity in control cells, after L-ga-
lactosidase normalization. Data are presented as the means þ S.E.M.
of three separate transfection experiments.
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substantiated by a previous study describing a direct MyoD/
retinoid receptor interaction [36]. Preliminary studies per-
formed in the laboratory also suggest the occurrence of such
a direct interaction, but probably involving a third protein
partner.
In conclusion, we have previously shown that inhibition of
AP-1 activity (c-Jun/c-Fos) by the hormone occurring since
RXR expression [9], leading to the expression of BTG1, an
antiproliferative protein inducing myoblast di¡erentiation [37]
is probably a crucial pathway involved in the myogenic T3
in£uence. In addition, this study suggests the occurrence of a
new mechanism possibly involved in a subtle control of myo-
blast terminal di¡erentiation by the thyroid hormone appa-
ratus. By inhibiting MyoD activity, T3RK1 could contribute
to maintain an optimal myoblast proliferation period, whereas
the induction of RXR expression at the onset of terminal
di¡erentiation [10] could allow the liganded T3 receptor to
inhibit AP-1 activity, a major myogenic repressor [38].
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